Janice M. Hodnefield

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau et al. · New England Journal of Medicine · 2007 · 919 citations · Full text

Medicine, Hematology, Pathology +17

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Mrinal M. Patnaik, Eric Padron, Rebecca R. Laborde et al. · Leukemia · 2013 · 219 citations

Medicine, Hematology, Oncology +16

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

Mrinal M. Patnaik, Terra L. Lasho, Janice M. Hodnefield et al. · Blood · 2011 · 202 citations · Full text

Medicine, Genetics, Hematology +12

Spliceosome mutations involving <i>SRSF2</i>, <i>SF3B1</i>, and <i>U2AF35</i> in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance

Mrinal M. Patnaik, Terra L. Lasho, Christy M. Finke et al. · American Journal of Hematology · 2012 · 151 citations

Life Sciences, Genetics, Hematology +11

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

Mrinal M. Patnaik, Curtis A. Hanson, Janice M. Hodnefield et al. · Leukemia · 2011 · 145 citations

Life Sciences, Genetics, Molecular Genetics +12